Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) — 分析摘要
Dr. Reddy's Laboratories Limited American Depositary Shares（RDY）的市值为9.87十亿美元，最近一年的营收同比增长了+14.2%。净利润率为17.6%。当前市盈率为14.6倍。
核心要点
- 营收同比变化+14.2%
- 净利润率17.6%
- 市盈率14.6倍
RDY的营收增长为+14.2%，市盈率为14.6倍。
Dr. Reddy's Laboratories Limited American Depositary Shares (RDY)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
员工人数
27,527
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.08
股息收益率
0.70%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。